XUANZHUBIO-B: NG-350A has been granted Fast Track designation by the U.S. FDA
I'm PortAI, I can summarize articles.
XUANZHUBIO-B announced that its product NG-350A has received Fast Track designation from the U.S. FDA for the treatment of locally advanced rectal cancer. This product is licensed from AkamisBio Ltd., and XUANZHUBIO has exclusive rights for development, production, and commercialization in the Greater China region. The FDA Fast Track designation is intended to expedite the development and review of potential drugs, particularly for the first therapies targeting serious diseases or those with significant clinical advantages
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments